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Diazoxide is an agonist of ATP sensitive K+ (KATP) channels in beta-cells and is used 
in the treatment of hyperinsulinism caused by insulinomas or Hyperinsulinism in 
Infancy (HI). The responsiveness of patients to diazoxide is highly variable and 
complicated by side-effects which include hypertension and hypertrichosis. The 
aim of this study was to examine the actions of a novel benzothiadiazine-
derivative, BPDZ-154, on beta-cell KATP channels and insulin release. We isolated 
human insulin-secreting cells from patients with HI (n=4) or adenoma (n=1) 
following surgery (with permission), and undertook additional studies using rat 
islets and the insulin-secreting cell-line BRIN-BD11. 
Results: BPDZ-154 was found to inhibit 16.7mM glucose-induced insulin release with 
an EC50 value of 0.28microM (compared to approximately 20microM for diazoxide). 
The mechanism of action of BPDZ-154 involved the selective activation of KATP 
channels since BPDZ-154 increased the activity of KATP channels in both intact 
cells (10-50microM, n=5) and in inside-out patches exposed to 500microM ATP, 
(10nM-50microM, n=23/23). BPDZ-154 was consistently found to be more potent 
than diazoxide (n=7/7) and was less readily reversible upon removal of the 
compound. Tolbutamide, and the imidazoline efaroxan reversed the effects of 
BPDZ-154 induced activation of KATP channels (n=13/13). In beta-cells isolated 
from HI patients, BPDZ-154 was effective in those patient tissues where KATP 
channel function remained (10-50microM, n=24/24), but was ineffective in patients 
where KATP channels were absent (n=10/10). In adenoma beta-cells, BDPZ-154 
consistently activated KATP channels (500microM ATP/ 10microM BPDZ-154, 
n=6/6). 
Summary: We document the inhibition of insulin release and activation of beta-cell 
KATP channels by BPDZ-154. BPDZ-154 was more potent than diazoxide. With 
improved selectivity for SUR1/Kir6.2 channels over non-beta-cell KATP channels 
these types of compounds may offer a therapeutic potential in the future 
treatment of HI. 
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